Trial Profile
Phase Ib/II Study of Radionuclide 177Lutetium-PSMA-617 Therapy in Combination With Pembrolizumab for Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRINCE
- 24 Oct 2023 Results (n=37) assessing the associations of PET imaging and circulating tumour cells features at baseline with department of prostate specific antigen (PSA) response, presented at the 48th European Society for Medical Oncology Congress.
- 13 Mar 2023 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology